Online citations, reference lists, and bibliographies.

A Cost-utility Analysis Of Treatment For Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP).

S. O'Brien, A. Ritchey, K. Smith
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The primary objective in the treatment of acute pediatric idiopathic thrombocytopenic purpura (ITP) is to rapidly increase the platelet count. METHODS We built a decision analytic model to evaluate the cost-utility of four commonly used treatment strategies: intravenous immunoglobulin G (IVIG) 0.8 g/kg, anti-D 75 mcg/kg, methylprednisolone (30 mg/kg for 3 days), and prednisone (4 mg/kg/day for 4 days). In our baseline model, all children were hospitalized upon presentation, and discharged once the platelet count reached > or =20,000. We performed a literature search to estimate time to platelet count > or =20,000 for each strategy, as well as the probability of side effects. We obtained cost data and quality of life measures from institutional and published data sources. RESULTS Total cost of one-time treatment for a 20 kg child was US dollars 786 with prednisone, US dollars 1,346 with methylprednisolone, US dollars 2,035 with anti-D, and US dollars 2,492 with IVIG. The strategies of IVIG and methylprednisolone were less effective and more expensive than anti-D and prednisone, respectively. Although anti-D caused the most rapid rise in platelet counts, the incremental cost-utility ratio (costs incurred by using anti-D instead of prednisone divided by health benefit of using anti-D instead of prednisone) was US dollars 7,616 per day of severe thrombocytopenia avoided, primarily due to the much higher medication cost of anti-D. Utilizing an outpatient model, the cost difference between anti-D and prednisone was even more striking. CONCLUSIONS The clinical benefit of anti-D is offset by a substantial cost increase. Although often overlooked in favor of newer agents, a brief course of high-dose prednisone is an inexpensive and effective treatment for acute ITP.
This paper references
10.3109/08880019309029508
Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
S. Ozsoylu (1993)
10.1080/08880010252899370
CLINICAL COURSE OF CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA TREATED WITH INTRAVENOUS IMMUNOGLOBULIN G OR MEGADOSE METHYLPREDNISOLONE OR OBSERVED WITHOUT THERAPY
F. Duru (2002)
10.1016/S0140-6736(01)07219-1
Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study
T. Kühne (2001)
Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study.
A. Dubansky (1989)
Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.
A. Freiberg (1998)
10.1055/S-2001-15257
Outcome measures and treatment endpoints other than platelet count in childhood idiopathic thrombocytopenic purpura.
G. Buchanan (2001)
10.1046/j.1365-2141.2001.02627.x
A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura
G. Newman (2001)
10.1002/(SICI)1096-8652(200003)63:3<156::AID-AJH9>3.0.CO;2-4
The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin
S. G. Sandler (2000)
10.1097/00043426-200210000-00008
Randomized Trial of High-Dose Methylprednisolone Versus Intravenous Immunoglobulin for the Treatment of Acute Idiopathic Thrombocytopenic Purpura in Children
K. G. Ancona (2002)
Safety profile of WinRho anti-D.
F. Hong (1998)
10.1177/0272989X0002000310
Willingness to Pay for a Quality-adjusted Life Year
R. Hirth (2000)
10.1097/00005650-199806000-00002
Toward consistency in cost-utility analyses: using national measures to create condition-specific values.
M. Gold (1998)
10.1016/S0022-3476(05)80400-7
A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.
V. Blanchette (1993)
10.1016/S0022-3476(88)80654-1
Pulse methylprednisolone therapy for acute childhood idiopathic thrombocytopenic purpura.
J. van Hoff (1988)
10.1080/08880010290097161
ANTI-D EXERTS A VERY EARLY RESPONSE IN CHILDHOOD ACUTE IDIOPATHIC THROMBOCYTOPENIC PURPURA
A. Moser (2002)
10.1097/00043426-200302000-00009
Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001
S. Vesely (2003)
10.1136/adc.71.3.251
Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology.
J. Lilleyman (1994)
10.1016/S1352-0237(00)00164-7
Bureau of Labor Statistics Web Site
J. Desposito (2000)
10.1159/000204392
Idiopathic thrombocytopenic purpura in Egyptian children.
A. Khalifa (1993)
10.1182/BLOOD.V88.1.3.BLOODJOURNAL8813
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
J. George (1996)
10.1055/S-2004-815628
Childhood acute immune thrombocytopenic purpura: 20 years later.
V. Blanchette (2003)
A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.
K. Fujisawa (2000)
10.1016/S0022-3476(99)70367-7
Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.
M. Tarantino (1999)
10.1002/AJH.20295
Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura
M. Kumar (2005)
10.1016/S0140-6736(94)92205-5
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura
V. Blanchette (1994)
10.1016/S0022-3476(05)82024-4
Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin.
D. Albayrak (1994)
10.1111/j.1651-2227.1996.tb14183.x
Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura
S. Rosthøj (1996)
A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura.
E. Erduran (2003)
10.1111/j.1651-2227.1998.tb01239.x
Short‐course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP)
M. Carcao (1998)
10.1097/00043426-200111000-00009
Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis
R. Klaassen (2001)
10.1097/00043426-199705000-00004
Safety and Efficacy of Low‐Dose Intravenous Immune Globulin (IVIG) Treatment for Infants and Children with Immune Thrombocytopenic Purpura
I. Warrier (1997)
10.1001/JAMA.1996.03540150055031
Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
M. Weinstein (1996)



This paper is referenced by
10.1007/s00277-010-0930-4
Evaluating bleeding severity in immune thrombocytopenia (ITP)
Cindy E Neunert (2010)
10.1002/PBC.21231
How far should we go with cost-utility analysis when treating children with acute idiopathic thrombocytopenic purpura?
M. Benesch (2008)
10.1080/14728214.2017.1294158
Emerging drugs for immune thrombocytopenia (ITP)
A. Salama (2017)
thrombocytopenic purpura Severe hemorrhage in children with newly diagnosed immune
J. Neufeld (2013)
10.4274/tjh.2014.0436
Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia
Ali Ayçiçek (2015)
10.1111/j.1365-2141.2009.08057.x
Comparison of intravenous immune globulin and high dose anti‐D immune globulin as initial therapy for childhood immune thrombocytopenic purpura
I. Kane (2010)
10.1542/peds.2012-2021
Patterns of Inpatient Care for Newly Diagnosed Immune Thrombocytopenia in US Children’s Hospitals
Courtney Kime (2013)
10.11412/JJPH1987.22.385
小児特発性血小板減少性紫斑病(ITP)のQOL調査成績 : 管理ガイドライン作成に向けて
純一 三間屋 (2008)
10.1002/pbc.24633
Anti-D immunoglobulin therapy for pediatric ITP: before and after the FDA's black box warning.
Joel C. Thompson (2013)
10.1016/j.hoc.2009.11.004
Childhood immune thrombocytopenic purpura: diagnosis and management.
V. Blanchette (2010)
10.1177/147323000803600324
Cost-effectiveness of Treatment for Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP) – a Systematic Review
M. Chen (2008)
Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
G. Blackhouse (2012)
10.1002/ccr3.1916
Eltrombopag in long‐term management of pediatric thrombocytopenia
S. Shah (2019)
10.1016/j.pcl.2008.01.004
Decision analysis in pediatric hematology.
S. O'Brien (2008)
10.1007/s40273-014-0171-9
A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding
Rosarin Sruamsiri (2014)
10.1016/J.ARCPED.2006.12.005
La prise en charge du purpura thrombopénique idiopathique en phase initiale : enquête auprès des membres de la Société française d'hématologie et d'immunologie pédiatrique (SHIP)
P. Lutz (2007)
10.1007/springerreference_73517
188 Quality of Life in Immune Thrombocytopenic Purpura: China Perspectives
Rongjia Yang (2010)
Membrane forces and key protein determinants of hematopoietic cell function: Lamins and myosin-II in hematopoiesis and CD47 in immunotherapy of cancer
Kyle R. Spinler (2014)
10.26719/2009.15.3.729
Immune thrombocytopenia in children with reference to low-income countries.
A. Rehman (2009)
10.1111/j.1365-2141.2008.07054.x
Rituximab in the treatment of autoimmune haematological disorders
B. Garvey (2008)
10.1053/j.seminhematol.2016.04.019
Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?
Joanne Yacobovich (2016)
10.1016/J.CPEM.2018.05.007
Breaking Down Blood: Pediatric Immune Thrombocytopenia and Autoimmune Hemolytic Anemia in the Emergency Department
Richard Graham (2018)
Rituximab in the treatment of autoimmune haematological disorders
St Michael’s (2008)
10.1002/pbc.21978
Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura.
C. Neunert (2009)
10.1093/tropej/fmq022
Short-course high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in children.
Dinesh Kumar Yadav (2010)
10.1002/pbc.22708
A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children.
J. Cooper (2010)
Canadian Agency for Drugs and Technologies in Health Intravenous Immunoglobulin for Treatment of Idiopathic Thrombocytopenic Purpura : Economic and Health Service Impact Analyses
G. Blackhouse (2008)
10.3111/13696998.2011.646045
Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue
Michaël Iskedjian (2012)
10.1016/j.pcl.2008.01.009
Childhood immune thrombocytopenic purpura: diagnosis and management.
V. Blanchette (2008)
10.1182/blood-2008-03-138487
Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.
C. Neunert (2008)
10.1177/0272989X11400417
Decision Modeling of Disagreements
Harold P. Lehmann (2011)
10.1007/s12098-019-03155-4
Immune Thrombocytopenia in Children: Consensus and Controversies
Gurpreet Singh (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar